Clinical Manifestations of Posttransplantation Lymphoproliferative Disorder (PTLD) after Liver Transplantation.
- Author:
Hyun Kyun KI
1
;
Kyong Mok SOHN
;
Yu Mi WI
;
Ji Young RHEE
;
Chi Sook MOON
;
Won Sup OH
;
Kyong Ran PECK
;
Jae Hoon SONG
;
Sung Ju KIM
;
Jae Won CHO
;
Suk Ku LEE
;
Young Hye KOH
Author Information
1. Division of Infectious Diseases, Department of Internal Medicine, Konkuk University, Korea.
- Publication Type:Original Article
- Keywords:
Liver transplantation;
Post-transplant lymphoproliferative disorder (PTLD);
EBV
- MeSH:
Acyclovir;
Adult;
Child;
Cyclosporine;
Diagnosis;
Early Diagnosis;
Female;
Herpesvirus 4, Human;
Humans;
Immunoglobulin G;
Immunosuppression;
Incidence;
Korea;
Liver Transplantation*;
Liver*;
Logistic Models;
Lymphoma, B-Cell;
Lymphoproliferative Disorders*;
Male;
Prevalence;
Prognosis;
Retrospective Studies;
Risk Factors;
Seoul;
Transplantation
- From:
Infection and Chemotherapy
2006;38(3):131-139
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Post-transplantation lymphoproliferative disorder (PTLD) after liver transplantation is a rare but potentially fatal disease. Clinical manifestations and prevalence of PTLD after liver transplantation in Korea have not been investigated thoroughly. MATERIALS AND METHODS: A retrospective chart review was done for 284 liver transplant recipients at Samsung Medical Center, Seoul, Korea during the period from 1996 to 2003. RESULTS: The incidence of PTLD after liver transplantation was 3.9% (11/284). PTLDs were more prevalent in children (9/55, 16.4%) than in adults (2/237, 0.9%; P<0.01). Among the PTLD patients, four cases were male (36.3%) and seven were female (63.7%). Median time from the transplantation to PTLD diagnosis was 9 months. The type of PTLD was as follows:early lesion (6 cases, 54.5%), polymorphic PTLD (3 cases, 27.3%), and B cell lymphoma (2 cases, 18.2%). PTLDs were more prevalent in the patients with cyclosporine use (OR 13.28, 95% CI:1.29-136.31, P=0.03), acute rejection (OR 5.63, 95% CI:1.03-30.62, P=0.04), and negative serology for EBV VCA IgG (OR 19.15, 95% CI:1.99-183.98, P=0.01) by multivariate logistic regression. Three patients (27.3%) died of B cell lymphoma (2 cases) and polymorphic PTLD (1 case). The remaining patients were improved with reduction of immunosuppression and treatment with acyclovir. CONCLUSION: The incidence of PTLD was high in children. The risk factors of PTLD were negative serology for EBV VCA IgG, history of acute rejection, and cyclosporine use. Considering the poor prognosis of PTLD, effective strategies for prevention and early diagnosis for early treatment should be emphasized.
